AMICUS THERAPEUTICS INC. overview

Kaskela Law LLC announces that it is investigating Amicus Therapeutics, Inc. (NASDAQ: FOLD) (“Amicus”) on behalf of the company’s shareholders. Click here for additional information: https://kaskelalaw.com/case/amicus-therapeutics/ Since December 2023, shares of Amicus’ common stock have declined in value from a trading price of $14.50 per share to a current trading price of approximately $11.00 per share, a decline of nearly 25% in value . The investigation seeks to determine whether...

WuXi Biologics Congratulates Amicus Therapeutics on U.S. FDA Approval for New Treatment for Pompe Disease PR Newswire WUXI, China, Oct. 1, 2023 WUXI, China , Oct. 1, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), congratulates its strategic partner, Amicus Therapeutics ("Amicus") (Nasdaq: FOLD), on receiving U.S. FDA's approval for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat)...

WuXi Biologics Congratulates Amicus Therapeutics on European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease PR Newswire WUXI, China, March 28, 2023 WUXI, China , March 28, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), congratulates its strategic partner Amicus Therapeutics ("Amicus") (Nasdaq: FOLD) on receiving European Commission's approval for Pombiliti™...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amicus Therapeutics, Inc. - FOLD PR Newswire NEW YORK, Nov. 14, 2022 NEW YORK , Nov. 14, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Amicus Therapeutics, Inc. ("Amicus" or the "Company") (NASDAQ: FOLD). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether Amicus and certain of its...

NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- ARYA Sciences Acquisition Corp IV (NASDAQ: ARYD) (“ARYA IV”), a publicly traded special purpose acquisition company sponsored by Perceptive Advisors announced today that, due to existing market conditions, it has mutually agreed with Amicus Therapeutics, Inc. (Nasdaq: FOLD) (“Amicus”) to terminate their previously announced Business Combination Agreement (the “Business Combination Agreement”), effective immediately. “While this is not the...

Thinking about buying stock in Applied UV, Fortress Biotech, Geovax Labs, Amicus Therapeutics, or Lucid Group? PR Newswire NEW YORK, Sept. 29, 2021 NEW YORK , Sept. 29, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AUVI, FBIO, GOVX, FOLD, and LCID. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. AUVI:...

Thinking about buying stock in Grupo Televisa, Phunware, Immunitybio, Flexion Therapeutics, or Amicus Therapeutics? PR Newswire NEW YORK, April 14, 2021 NEW YORK , April 14, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TV, PHUN, IBRX, FLXN, and FOLD. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. TV:...